Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected
Stopped early · Phase 3
Conditions studied: Ovarian Cancer
In brief
The objective of this study was to assess the efficacy and safety of the combination of alpelisib and olaparib compared with single agent cytotoxic chemotherapy in patients with platinum resistant or refractory high-grade serous ovarian cancer, with no germline BRCA mutation detected.
Key facts
- Study ID
- NCT04729387
- Run by
- Novartis Pharmaceuticals
- People needed
- 358
- Starts
- 2021-07-22
- Expected to finish
- 2026-01-19
- Last updated by the study team
- 2026-06-04
Who can join
Age: 18 and older, up to 100. Sex: any. Healthy volunteers: not accepted.
Where it is running
- HonorHealth — Phoenix, Arizona, United States
- Florida Cancer Specialists — Fort Myers, Florida, United States
- Florida Cancer Specialists — West Palm Beach, Florida, United States
- Maryland Oncology Hematology P A — Silver Spring, Maryland, United States
- Massachusetts General Hospital — Boston, Massachusetts, United States
- Dana Farber Cancer Institute — Boston, Massachusetts, United States
- Memorial Sloan Kettering Cancer Ctr — New York, New York, United States
- Oncology Hematology Care Inc — Cincinnati, Ohio, United States
- University Of Cincinnati — Cincinnati, Ohio, United States
- Avera Cancer Institute — Sioux Falls, South Dakota, United States
- Tennessee Oncology — Nashville, Tennessee, United States
- Texas Oncology — Amarillo, Texas, United States
- Texas Oncology P A — Bedford, Texas, United States
- Texas Oncology P A — San Antonio, Texas, United States
- Texas Oncology Northeast Texas — Tyler, Texas, United States
- Novartis Investigative Site — CABA, Buenos Aires, Argentina
- Novartis Investigative Site — Buenos Aires, Argentina
- Novartis Investigative Site — Caba, Argentina
- Novartis Investigative Site — Bedford Park, South Australia, Australia
- Novartis Investigative Site — Shepparton, Victoria, Australia
- Novartis Investigative Site — Sydney, Australia
- Novartis Investigative Site — Innsbruck, Tyrol, Austria
- Novartis Investigative Site — Graz, Austria
- Novartis Investigative Site — Brussels, Belgium
- Arizona Oncology Associates — Phoenix, Arizona, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.